Transcend Capital Advisors LLC Takes Position in argenex SE (NASDAQ:ARGX)

Transcend Capital Advisors LLC acquired a new stake in shares of argenex SE (NASDAQ:ARGX - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 577 shares of the company's stock, valued at approximately $342,000.

Several other institutional investors and hedge funds have also bought and sold shares of ARGX. GeoWealth Management LLC lifted its stake in argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares during the period. Rakuten Securities Inc. lifted its stake in argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares during the period. Whipplewood Advisors LLC acquired a new stake in argenex during the 4th quarter valued at approximately $37,000. Global Retirement Partners LLC lifted its stake in argenex by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares during the period. Finally, FIL Ltd acquired a new stake in argenex during the 4th quarter valued at approximately $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Down 1.6%

Shares of argenex stock traded down $8.75 during trading hours on Tuesday, reaching $542.47. 606,590 shares of the company's stock were exchanged, compared to its average volume of 328,466. argenex SE has a 1 year low of $429.27 and a 1 year high of $678.21. The company has a market capitalization of $33.12 billion, a P/E ratio of 33.47, a price-to-earnings-growth ratio of 1.00 and a beta of 0.37. The business has a fifty day moving average of $580.69 and a two-hundred day moving average of $606.71.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%. As a group, research analysts predict that argenex SE will post 3.13 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on ARGX shares. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenex in a research note on Tuesday. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $715.00 target price on shares of argenex in a research note on Tuesday, June 24th. Finally, Oppenheimer boosted their target price on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, argenex has an average rating of "Buy" and an average price target of $729.93.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.